To the Editor,

We thank you for your comments on our study published in the September 2014 issue of The Anatolian Journal of Cardiology entitled "Assessment of serum hepcidin levels in patients with non-ST elevation myocardial infarction (NSTEMI)." ([@ref1]). They have raised some questions. Hepcidin is produced mainly in the liver and increases in response to inflammation, and its expression is regulated by anemia, hypoxia, and inflammation ([@ref2]). In this single-center study, we evaluated whether the level of hepcidin increased in the acute phase in NSTEMI, known as acute inflammatory aggravation of a chronic atherosclerotic process.

There are conflicting results for hepcidin in coronary artery disease patients ([@ref3], [@ref4]). The first remark was about blood sampling time and symptom onset. We did not investigate hepcidin kinetics in this study; our aim was fundamentally to use hepcidin as a new cardiac marker instead of troponin. Another remark was about the time interval between the onset of the symptoms and blood sampling. According to our study design, we aimed to compare hepcidin levels with troponin levels in the diagnosis of NSTEMI. It is important that the hepcidin levels did not increase; meanwhile, the levels of troponin were increased in NSTEMI patients in the acute phase. The observed differences in these parameters, performed simultaneously from the same patients, forced us to think that there was no need to take the time interval between the onset of symptoms and blood sampling. The other remark was about the study of Suzuki et al. ([@ref4]). The patient population and the design of the two studies were different, as the authors ([@ref4]) studied ST elevation myocardial infarction patients, but we did not. Also, the sample of their study was extremely low, and their aim was also different. As stated in the criticism, if we performed a correlation analysis between CRP and hepcidin levels, it should have corroborated our results, showing hepcidin as a surrogate marker of inflammation.
